Portrays Māori and Pasifika as medically justified priority recipients of targeted diabetes treatment based on higher disease risk.
The framing emphasizes clinical data and scientific rationale to support ethnicity-based treatment access, positioning Māori and Pasifika as groups with higher biological and epidemiological risk, thus deserving of targeted care.
“And we have strong clinical data to suggest that the maximum health benefit for dollars spent is obtained by targeting Māori and Pacific Island New Zealanders for these new, effective and admittedly quite expensive diabetes therapies.”
